Evidence map›Paper›PMID 42475673›Full record

ArticleJMIR mHealth and uHealth2026

A Personal Health App and Wearable Co-Design Framework for Rare and Complex Diseases: User-Centered, Collaborative Co-Design Study.

Sarah Margaret Goodday, Emma Karlin, Madeleine Sorensen, Robin Yang, Paul Gordon, Caresse Opoku, Daniel Vuong, Jenee Wilson, Diane McKenzie, Jules Piccotti and 24 more

Abstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Sarah Margaret GooddayDepartment of Psychiatry, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-2159-1754
Emma Karlin4YouandMe, New York, NY, United States.ORCID 0000-0002-5939-3078
Madeleine Sorensen4YouandMe, New York, NY, United States.ORCID 0000-0002-9747-4178
Robin Yang4YouandMe, New York, NY, United States.ORCID 0000-0001-9467-7044
Paul Gordon4YouandMe, New York, NY, United States.ORCID 0009-0000-4129-0743
Caresse Opoku4YouandMe, New York, NY, United States.ORCID 0009-0005-6097-6149
Daniel Vuong4YouandMe, New York, NY, United States.ORCID 0009-0005-7108-4461
Jenee Wilson4YouandMe, New York, NY, United States.ORCID 0009-0002-4924-755X
Diane McKenzie4YouandMe, New York, NY, United States.ORCID 0009-0005-9959-3954
Jules PiccottiAgileOps, Siena, Italy.ORCID 0009-0004-1148-065X
Massimiliano TavantiAgileOps, Siena, Italy.ORCID 0009-0008-4051-6630
Megan FitzgeraldPatient-Led Research Collaborative, Calabasis, DC, United States.ORCID 0000-0002-4787-6208
Yochai Re'emPatient-Led Research Collaborative, Calabasis, DC, United States.ORCID 0000-0002-9117-764X
Hannah WeiPatient-Led Research Collaborative, Calabasis, DC, United States.ORCID 0000-0002-0307-7498
Megan GoldenMission: Cure, New York, NY, United States.ORCID 0009-0008-5155-4819
Daniel MorganMission: Cure, New York, NY, United States.ORCID 0009-0005-3311-2812
Michele ManionPrimary Ciliary Dyskinesia (PCD) Foundation, Rochester, NY, United States.ORCID 0000-0001-6683-2326
Ricardo MosqueraDepartment of Pediatrics, The University of Texas Health Science Center at Houston, Houston, TX, United States.ORCID 0000-0002-5350-331X
Tricha ShivasFoundation for Sarcoidosis Research, Chicago, IL, United States.ORCID 0000-0002-2253-9520
Elise HooverFoundation for Sarcoidosis Research, Chicago, IL, United States.ORCID 0000-0003-0119-3724
Allison PeckCure VCP Disease Inc., Warner Robins, GA, United States.ORCID 0009-0000-5222-9825
Nathan PeckCure VCP Disease Inc., Warner Robins, GA, United States.ORCID 0009-0006-4562-5583
Zollie YavarowCure VCP Disease Inc., Warner Robins, GA, United States.ORCID 0000-0002-5299-3599
Heidi Bjornson-PennellBiohub, San Francisco, CA, United States.ORCID 0009-0001-4106-7151
Andra StrattonBiohub, San Francisco, CA, United States.ORCID 0009-0007-7875-0417
Samali Anova SahooUniversity of Pennsylvania, Philadelphia, PA, United States.ORCID 0009-0003-6000-5946
Douglas ArbittierUniversity of Pennsylvania, Philadelphia, PA, United States.ORCID 0009-0007-0018-7003
Elizabeth ArbittierUniversity of Pennsylvania, Philadelphia, PA, United States.ORCID 0009-0003-0561-0764
Renee Goff4YouandMe, New York, NY, United States.ORCID 0009-0003-3172-5725
Donna Harvin-Graham4YouandMe, New York, NY, United States.ORCID 0009-0002-0275-1409
Nancy HowardFoundation for Sarcoidosis Research, Chicago, IL, United States.ORCID 0000-0002-6386-1559
Camille KnudsenCure VCP Disease Inc., Warner Robins, GA, United States.ORCID 0009-0006-1204-5902
Mary Oldham4YouandMe, New York, NY, United States.ORCID 0009-0006-2426-0351
Stephen FriendDepartment of Psychiatry, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-0830-7600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnd user co-design in the personal digital health technology space is underdeveloped. Clinical uptake of personal digital health technologies has been poor, highlighting a need to cocreate solutions with end users.

objectiveThe study aimed to describe an "end user" co-design framework in the development of 5 prototype personal health apps for patients with different rare or complex diseases.

methodsA patient-led, user-centered, collaborative personal health app plus wearable plug-in co-design methodology was developed. Five prototype apps were developed for end users with long COVID-19, pancreatitis, primary ciliary dyskinesia, sarcoidosis, and valosin-containing protein disease by a multidisciplinary partnership including patients, app design and development experts, user experience experts, clinicians, and patient-driven organizations. Phase 1 involved a 6-month co-design process with 5 modules involving patient-driven organizations that included the codevelopment of specifications through group workshops and independent exercises that defined the goals, content, features, and user experience of each app. Phase 2 involved app build-out, internal alpha testing, and beta study preparations. Phase 3 involved a usability beta testing study in which end users used the app and associated wearable/smart devices (Oura ring, Lumia ear device, Empatica EmbracePlus, and MIR Spirobank Spirometer) for up to 5 months. Participant feedback was documented continuously and systematically, centering on the following themes: functionality, usability, harms, benefits, self-explorations, and beta testing study details related to retention and adherence.

resultsWhile unique app goals were codeveloped by each disease group, a central goal across groups was to develop a personal health app enabling users to track subjective, self-reported symptoms, objective measures of health, and unique modifiers of symptoms. A total of 239 end user participants participated in the beta testing pilot study. Enrollment and retention rates were high, ranging from 94% to 100% and 92.2% to 100%, respectively. All active participants gave some form of feedback: there were 257 unique participant suggestions of how to specifically modify or improve the study app experience. Participant feedback themes commonly centered around customization to reduce daily burden and improve personal tailoring of the app. Participants' desires surrounding symptom displays were heterogeneous.

conclusionsPersonal health app co-design is rooted in a complex digital landscape that requires a significant amount of up-front effort and time. However, the up-front investment of time can result in rich and diverse end user feedback that could save time in the app development trajectory to implementation. This paper provides a co-design framework and the building blocks of 5 prototype personal health apps with publicly available open-source code on GitHub. These prototypes could be leveraged for improving understanding of, communicating symptoms of, and providing n-of-1 suggestions for rare or complex diseases, providing benefit to patient communities and individual patients.

Indexed as

Mobile ApplicationsRare DiseasesUser-Centered DesignWearable Electronic DevicesCOVID-19Digital HealthFemaleHumansMaleSARS-CoV-2Telemedicineco-designdigital healthl ong COVID-19mobile healthpancreatitisPCDprimary ciliary dyskinesiasarcoidosisuser-centeredvalosin-containing proteinVCP diseasewearables

Identifiers

PMID42475673
PMCPMC13434255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.